Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
RAPT Therapeutics, Inc. - Common Stock
(NQ:
RAPT
)
57.68
+0.05 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RAPT Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Why Is Inflammatory Disease/Oncology-Focused RAPT Therapeutics Shares Tumbling Today?
↗
February 20, 2024
FDA places clinical hold on RAPT Therapeutics' Phase 2 trials for zelnecirnon in atopic dermatitis and asthma.
Via
Benzinga
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
↗
February 20, 2024
The FDA put studies in eczema and asthma treatment on clinical hold.
Via
Investor's Business Daily
Dow Dips Over 100 Points; US Leading Economic Index Falls In January
↗
February 20, 2024
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 while the NASDAQ fell 1.51% to 15,537.95. The S&P 500...
Via
Benzinga
Topics
Stocks
Dow Rebounds; Nasdaq Drops Triple Digits
↗
February 20, 2024
Nvidia stock is sliding ahead of tomorrow's earnings report
Via
Talk Markets
Topics
Stocks
Nasdaq Down 1%; Capital One Set To Buy Discover
↗
February 20, 2024
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Recap: RAPT Therapeutics Q3 Earnings
↗
November 13, 2023
Via
Benzinga
Analyst Ratings for RAPT Therapeutics
↗
September 14, 2023
Via
Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
↗
August 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 20, 2024
Via
Benzinga
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
February 13, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for RAPT Therapeutics
↗
June 05, 2023
Via
Benzinga
Analyst Expectations for RAPT Therapeutics's Future
↗
May 12, 2023
Via
Benzinga
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 27, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
Company maintains strong cash position of $184.8 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Recap: RAPT Therapeutics Q1 Earnings
↗
May 11, 2023
Via
Benzinga
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
November 01, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 18, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
↗
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
↗
September 14, 2023
Via
Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
Company maintains strong cash position of $205 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
↗
August 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
↗
June 15, 2023
Via
Benzinga
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
Company maintains strong cash position of $231.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
